A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
Authors
Keywords
-
Journal
Cancer Immunology Research
Volume 11, Issue 9, Pages 1237-1252
Publisher
American Association for Cancer Research (AACR)
Online
2023-06-28
DOI
10.1158/2326-6066.cir-23-0189
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
- (2023) Roeland Lameris et al. Cell Reports Medicine
- Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
- (2022) José Saura-Esteller et al. Frontiers in Immunology
- A bispecific single domain antibody boosts autologous Vγ9Vδ2-T cell responses towards CD1d in chronic lymphocytic leukemia
- (2021) Iris de Weerdt et al. CLINICAL CANCER RESEARCH
- Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
- (2021) Jim Middelburg et al. Cancers
- CAR-T cells and BiTEs in solid tumors: challenges and perspectives
- (2021) Julien Edeline et al. Journal of Hematology & Oncology
- Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
- (2020) Marc Rigau et al. SCIENCE
- GPA33: A Marker to Identify Stable Human Regulatory T Cells
- (2020) Rianne Opstelten et al. JOURNAL OF IMMUNOLOGY
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia
- (2018) Piamsiri Sawaisorn et al. IMMUNOLOGICAL INVESTIGATIONS
- The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness
- (2018) Daisy Melandri et al. NATURE IMMUNOLOGY
- CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
- (2018) Kerstin Schütze et al. Frontiers in Immunology
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- The level of epidermal growth factor receptors expression is correlated with the advancement of colorectal adenoma: validation of a surface biomarker
- (2017) Nicolas Williet et al. Oncotarget
- Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays
- (2017) Marie Tosolini et al. OncoImmunology
- A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
- (2017) Renée C. G. de Bruin et al. OncoImmunology
- Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications
- (2016) Renée C.G. de Bruin et al. CLINICAL IMMUNOLOGY
- Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features
- (2016) Roeland Lameris et al. IMMUNOLOGY
- CD8αβ+γδ T Cells: A Novel T Cell Subset with a Potential Role in Inflammatory Bowel Disease
- (2016) Mohammad Kadivar et al. JOURNAL OF IMMUNOLOGY
- Evolution and function of the TCR Vgamma9 chain repertoire: It’s good to be public
- (2015) C. David Pauza et al. CELLULAR IMMUNOLOGY
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells
- (2014) H.-H. Oberg et al. CANCER RESEARCH
- Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
- (2013) Karl R. Schmitz et al. STRUCTURE
- Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human T-cell subset
- (2012) C. Harly et al. BLOOD
- Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
- (2012) Adriana Cordova et al. PLoS One
- Human MAIT and CD8 cells develop from a pool of type-17 precommitted CD8+ T cells
- (2011) L. J. Walker et al. BLOOD
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
- (2011) A J Nicol et al. BRITISH JOURNAL OF CANCER
- A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
- (2011) Rob C. Roovers et al. INTERNATIONAL JOURNAL OF CANCER
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis
- (2010) Daiko Wakita et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- Efficient Killing of Human Colon Cancer Stem Cells by T Lymphocytes
- (2009) M. Todaro et al. JOURNAL OF IMMUNOLOGY
- Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma
- (2009) Nichole L. Bryant et al. NEURO-ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More